StockData

Cardiff Oncology vs PharmaCyte Biotech

CRDF and PMCB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRDF and PMCB compare

Cardiff Oncology and PharmaCyte Biotech are about the same size, with market caps of $65.8M and $58.2M.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRDFPMCB
Size and price
Market cap$65.8M$58.2M
Share price$0.846$5.42
Change, 1 year−60.3%589%
Change, 5 years−84.9%−88.6%
Beta (5Y)2.50–
Employees312
StockData Score
Total score77
Valuation score01 (better)
Growth score1 (better)0
Performance score11
Health score55
Dividend score00
Valuation
P/S130×–
P/B2.5×2.1× (better)
Growth
Revenue growth (TTM)−7.0%–
Revenue growth, 5Y average10.1%–
Net income growth (TTM)–−163%
Profitability
Operating margin−8320%–
Net margin−7884%–
Return on equity−94.1%−48.9% (better)
Return on invested capital–−23.5%
Financial health
Debt / equity0.000.00
Current ratio3.3040.30 (better)
Altman Z-score−16.201.26 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield–0.69%
Shareholder yield0.00%0.69% (better)
Ownership
Held by institutions24.2%7.1%
Held by insiders4.9%7.1%
Insider net buying, 12 months$1.1M (better)$129K
Short interest, % of float16.6%0.51%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.